Anbieterkennzeichnung gemäss § 6 TDG (Teledienstegesetz)
Identification of offering party according to german teleservice law §6

Address: Profil Institut für Stoffwechselforschung GmbH
Hellersbergstraße 9 · 41460 Neuss · Germany

Geschäftsführung / CEO: Dr. Tim Heise, Dr. Christoph Kapitza
Handelsregister / Trade register: Amtsgericht Neuss, HRB 9712
Umsatzsteuer-Identifikationsnummer / Tax identification number: DE 199603332

Contact

Phone: +49 2131 4018-0
Fax: +49 2131 4018-500
E-mail: marketing(at)profil.com

360 peer-reviewed scientific publications (impact factor > 1.000)

Profil’s experts have published more than 360 papers in peer-reviewed journals with a cumulated impact factor > 1.000. Furthermore, they presented more than 500 abstracts at scientific conferences and held more than 380 oral presentations at national and international conferences.

The recent publications you will find here, for earlier ones please contact us: marketing(at)profil.com.

Recent Publications

• Vora J, Heise T.
• Variability of glucose-lowering effect as a limiting factor in optimising basal insulin therapy. A review.
• DIABETES OBES METAB. Accepted manuscript online: 1 MAR 2013 06:08PM EST | DOI: 10.1111/dom.12087
• Heise T, Seewald-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Wörle HJ.
• Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 week´s treatment with empagliflozin once daily in patients with type 2 diabetes.
• DIABETES OBES METAB. 2013 Jan 28. doi: 10.1111/dom.12073.[Epub ahead of print]
• Kapitza C, Forst T, Cöster HV, Poitiers F, Ruus P, Hincelin-Mery A.
• Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
• DIABETES OBES METAB. 2013 Jan 31. doi: 10.1111/dom.12076. [Epub ahead of print]
• Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, HeiseT.
• Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
• DIABETES OBES METAB. 15(1):77-83, 2013
• Arnolds S, Heckermann S, Koch C, Heissmann N, Sawicki PT.
• How do patients' Exp Clin Endocrinol Diabetespreferences compare to the present spectrum of diabetes research?
• EXP CLIN ENDOCRINOL DIABETES 121(1): 60-63, 2013
• Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S.
• Continuous glucose monitoring: quality of hypoglycaemia detection.
• DIABETES OBES METAB 15(2):130-135, 2013
• Barkai L, Gurieva I, Stirban A, Tesfaye S, Czupryniak L, Mankovsky BN, Spallone V, Veresiu IA, Schnell O, Kempler P.
• Microvascular complications in children and adolescents with type 1 diabetes.
• DIABETES, STOFFWECHSEL UND HERZ 21: 309-315, 2012
• Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, HeiseT, Becker RH
• Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
• DIABETES CARE 35(12): 2626 – 2630, 2012
• Buehlmeier J, Frings-Meuthen P, Remer T, Maser-Gluth C, Stehle P, Biolo G, Heer M.
• Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: Results of a randomized controlled trial.
• J CLIN ENDOCRINOL METAB. 97(12): 4789-4797, 2012
• Caduff A, Heinemann L, Talary MS, Di Benedetto G, Lutz HU, Theander S.
• A 4-h hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects.
• ACTA DIABETOLOGIA 49(5):333-339, 2012
• Facchinetti A, Sparacino G, Guerra S, Luijf M, De Vries JH, Mader JK, Ellmerer M, Benesch C, Heinemann L, Bruttomesso D, Avogaro A, Cobelli C.
• Real-time improvement of continuous glucose-monitoring accuracy: the smart sensor concept.
• DIABETES CARE PMID: 23172973 (Epub ahead of print), 2012
• Heise T; Merker L, Matthaei S.
• Insulin degludec: Ein neues, ultra-langwirksames Basalinsulin.
• DIABETES, STOFFWECHSEL UND HERZ 21: 231-238, 2012
• Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H.
• Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
• DIABETES OBES METAB. 14(10): 944-950, 2012
• Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H.
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
• DIABETES OBES METAB 14(9): 859-864, 2012
• Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
• Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
• DIABETES RES CLIN PRACT. 97(2): 258-266, 2012
• Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader JK, De Vries JH.
• Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center.
• J DIABETES SCI TECHNOL. 6(5): 1103-1106, 2012
• McVey E, Hirsch L, Sutter DE, Kapitza C, Dellweg S, Clair J, Rebrin K, Judge K, Pettis RJ.
• Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
• J DIABETES SCI TECHNOL. 6(4):743-754, 2012
• Meier JJ, Pennartz C, Schenker N, Menge BA, Schmidt WE, Heise T, Kapitza C, Veldhuis JD.
• Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
• DIABETES OBES METAB. PMID: 23039360 (Epub ahead of print), 2012
• Morgan JL, Zwart SR, Heer M, Ploutz-Snyder R, Ericson K, Smith SM.
• Bone metabolism and nutritional status during 30-day head-down tilt bed rest.
• J APPL PHYSIOL. 113(10):1519-1529, 2012
• Nosek L, Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, Fischer A, Heise T.
• Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
• DIABETES OBES METAB. 14(12):1137-1144, 2012
• Plum L, Lin HV, Aizawa K, Liu Y, Wardlaw SL, Accili D.
• InsR/FoxO1 signaling curtails hypothalamic POMC neuron number.
• PLoS ONE 7: e31487, 2012
• Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, Dugi KA, Heise T.
• Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
• DIABETES THER. 3(1):10.1007/s13300-012-0010-y [doi]
• Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, Plum L, Arancio O, Accili D.
• FoxO1 target Gpr17 activates AgRP neurons to regulate food intake.
• CELL 149(6): 1341–1326, 2012
• Smith SM, Heer M, Wang Z, Huntoon CL, Zwart SR.
• Long-duration space flight and bed rest effects on testosterone and other steroids.
• JCEM 97(1):270-8, 2012
• Smith SM, Heer M, Shackelford L, Sibonga JD, Ploutz-Snyder L, Zwart SR.
• Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry.
• J BONE MINER RES. 27(9):1896-906, 2012
• Stirban A, Dellweg S.
• Neue Methoden zur Diagnose mikrovaskulärer Komplikationen.
• DIABETES CONGRESS REPORT 5: 22-25, 2012
• Stirban A, Nandrean S, Kirana S, Götting C, Veresiu IA, Tschoepe D.
• Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
• MED. doi:10.1155/2012/968761, 2012
• Stirban A, Kotsi P, Franke K, Strijowski U, Cai W, Götting C, Tschoepe D.
• Acute macrovascular dysfunction in patients with type 2 diabetes mellitus induced by ingestion of advanced glycated betalactoglobulins.
• DIABETES CARE doi: 10.2337/dc12-1489, 2012
• Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC.
• Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
• PLoS One 7(3):e33108, 2012
• Thomas A, Heinemann L.
• Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
• J DIABETES SCI TECHNOL. 6(3): 572-580, 2012
• Zwart SR, Gibson CR, Mader TH, Ericson K, Heer M, Smith SM.
• Vision changes after spaceflight are related are related to alterations in folate- and vitamin B-12 dependent one-carbon metabolism.
• J NUTR. 142(3): 427-31, 2012
• Heer M.
• An analysis of the effect of olibra: a 12-week randomized control trial and a review of earlier studies.
• J DIABETES SCI TECHNOL 6(3): 709-711, 2012
• Tigges C, Heer M.
• The second-meal effect: can meal-skipping and nutrient composition of a meal affect postprandial blood glucose levels from a subsequent meal?
• DIABET NUTRITJE RISK CARDIOMETABOLIC 3: 33-39, 2012
• Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A.
• Für die Arbeitsgruppe CGM der Arbeitsgemeinschaft Diabetologische Technologie der DDG (AGDT) Evidenz und Konsens für den klinischen Einsatz von CGM.
• DIABETES, STOFFWECHSEL UND HERZ 1: 32-47, 2012
• Stirban A, Nandrean S, MD, Kirana S, Christian Götting C, Andrei Veresiu IA, Tschoepe D.
• Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
• INT J VASC MED, Volume 2012, Article ID 968761, doi:10.1155/2012/968761